New HCPCS Code Approved: What Buy-and-Bill Drug Manufacturers Must Do Next
For pharmaceutical manufacturers launching or managing buy-and-bill products, securing a unique Healthcare Common Procedure Coding System (HCPCS) code is a highly anticipated and critical milestone. It transitions a product from the uncertainty of miscellaneous or unclassified coding to a standardized identifier that facilitates electronic claims routing and streamlined billing.
Receiving a new unique HCPCS code is not the end of launch execution; it is merely the transition into the operational phase of market access. Without proactive post-assignment management, manufacturers risk severe disruptions in claims adjudication, provider frustration, and delayed revenue. To ensure successful market uptake and seamless reimbursement, manufacturers must execute a highly coordinated strategy immediately following code assignment.
Common Post-Assignment Launch Mistakes
Even with a dedicated strategy, manufacturers frequently stumble during the HCPCS transition. Avoid these common pitfalls:
Assuming Automatic Payer Updates: Believing that commercial payers will automatically load and activate the new code on the CMS effective date. (Many require manual intervention or proactive manufacturer outreach).
Neglecting the Miscellaneous Code Transition: Failing to clearly instruct providers on exactly when to stop using the unclassified code (e.g., J3490/J3590) and begin using the specific J-code. Billing the old code past the effective date triggers immediate denials.
Ignoring claims processing intermediaries such as Clearinghouses, EHR Vendors, Practice Management Software Vendors and Prior Authorization Vendors. These vendors need time to update their proprietary systems with the new code logic.
Post-Coding Launch Support Matters
Directive Strategy Group consultants have helped clients secure more than 50 new codes. Once new coding is in place, the focus should shift quickly to post-code launch execution—including payer education, claims system readiness, coding implementation, and reimbursement alignment.
To support these post-coding efforts, Directive Strategy Group recommends partnering with BuyandBill.com to help ensure successful implementation following HCPCS approval. BuyandBill.com helps manufacturers confirm HCPCS code load and validate NDC crosswalk accuracy. Reimbursement updates are communicated through payer alert email announcements, while claims system readiness is verified through live claims system confirmation. These efforts help support reimbursement alignment and a smoother path to product adoption. Examples can be found at https://buyandbill.com/newsletter/.
Critical Actions Immediately Following Code Assignment
To mitigate access barriers and build provider confidence, commercial, market access, and reimbursement teams should align on the following ten critical actions.
1. Confirm Effective Date, Descriptor, and Site-of-Care Implications
Thoroughly review the Centers for Medicare & Medicaid Services (CMS) publication to verify the code descriptor matches the product’s dosing and administration requirements. Manufacturers must confirm the effective date and understand any site-of-care implications, as reimbursement mechanics can vary significantly between the physician office setting and the hospital outpatient department (HOPD).
2. Ensure NDC-to-HCPCS Crosswalk Accuracy
Payers rely on accurate crosswalks linking the National Drug Code (NDC) to the new HCPCS code. Manufacturers must monitor internal and external data feeds to ensure the NDC-to-HCPCS mapping is accurate across major payer systems. An incorrect billing multiplier or mismatched package size can result in automatic claim rejections or severe underpayments.
3. Validate Pricing Compendia Listings
Claims systems draw critical pricing data from established compendia such as Red Book, Medi-Span, First Databank (FDB), and Gold Standard. Manufacturers must actively audit these databases to verify that the product is listed correctly under the new HCPCS code and that essential benchmarks (WAC, AWP) are accurately reflected.
4. Communicate Coding, Billing, and Pricing to Payers and Providers
Do not assume stakeholders will independently identify the coding update. Implement a targeted communication campaign:
Payers: Dispatch payer alerts detailing the new code, descriptor, NDC crosswalk, and associated diagnosis (ICD-10) and administration (CPT) codes and WAC pricing to facilitate swift medical policy and claims system updates.
Providers: Distribute updated billing and coding guides, emphasizing the transition date from the miscellaneous code to the permanent code.
5. Support Temporary Reimbursement Logic Before ASP is Established
Because Medicare requires one full quarter of reporting and one additional quarter to process and publish an Average Sales Price (ASP), initial reimbursement may default to Wholesale Acquisition Cost (WAC) plus a designated percentage, or Average Wholesale Price (AWP) minus a percentage. Manufacturers must educate providers and payers on these temporary pricing benchmarks to minimize confusion during the interim period.
6. Monitor Pass-Through, C-Code, J-Code, or Q-Code Impacts
Depending on the product and setting, CMS may issue a temporary C-code for HOPD pass-through status before assigning a permanent J-code or Q-code. Manufacturers must track these transitions closely, as the shift from a temporary to a permanent code requires providers to update their charge masters and billing systems promptly to avoid denials.
7. Verify Payer Claims System Loading and Adjudication Readiness
A published code does not guarantee payer systems are ready to accept it. Manufacturers should conduct payer claims system research—through outbound verification calls—to confirm that major commercial and Medicare/Medicaid plans have loaded the HCPCS code, activated it for billing, mapped it to the correct NDC codes, and have access to the WAC and AWP pricing to calculate the correct payment logic.
8. Track Denials, Underpayments, and Miscoding Trends
In the first 90 days following a code change, field reimbursement managers and patient support hubs should closely monitor claim remittances. Rapidly identifying patterns of denials (e.g., incorrect units billed, missing NDCs, or obsolete miscellaneous codes) allows the manufacturer to intervene with targeted provider education or payer outreach.
9. Align Field Reimbursement, Market Access, and Account Teams
Internal alignment is paramount. Ensure that all customer-facing teams—including Key Account Managers, Field Reimbursement Managers, and Medical Science Liaisons—are trained on the new coding landscape. Provide them with approved, compliant messaging and leave-behinds to address provider concerns confidently.
10. Prepare for ASP Reporting and Future Reimbursement Transitions
As the product matures, accurate ASP reporting to CMS becomes a critical compliance and commercial requirement. Manufacturers must establish robust internal controls for calculating and reporting ASP, preparing for the eventual transition when payers shift from WAC/AWP-based logic to ASP-based reimbursement.
Disclaimer: The coding guidance and regulatory requirements described in this article are provided for general informational purposes. Coding logic and reimbursement mechanics vary by payer and setting. Hospitals and manufacturers should consult with compliance, legal, and coding counsel prior to implementing changes.
